Market News & Trends
Fortress Biotech & Cyprium Therapeutics Announce $4.1-Million Grant From NINDS to Further Develop Gene Therapy for Menkes Disease
Cyprium Therapeutics, Inc. recently announced the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded a 3-year…
One of Northern Europe’s Largest Production Sites Successfully Taken Over by the Prange Group & Adragos Pharma
The Prange Group and its affiliate Adragos Pharma, one of Europe’s fastest growing CDMOs, has completed the acquisition transaction of Fresenius Kabi production site in…
Kinnate Biopharma Sells Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories
Kinnate Biopharma Inc. and Pierre Fabre Médicament, SAS recently announced their agreement to the sale of the company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF…
Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations
Nanoform Finland Plc recently announced it had received positive results from its own preclinical, in-vivo study of a nanocrystalline-enabled apalutamide oral formulation, which shows potential…
BioCina & NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance & Drug Product Solutions
BioCina Pty Ltd. and NovaCina Pty Ltd. recently announced a strategic partnership to provide integrated drug substance and drug product solutions for….
Idorsia & Viatris Enter Significant Global Research & Development Collaboration
Idorsia Ltd recently announced it has entered into agreements for a significant global research and development collaboration with Viatris Inc. for the global development and commercialization of two….
Simtra BioPharma Solutions Announces $250+ Million Investment to Expand Sterile Fill/Finish Manufacturing Site
Simtra BioPharma Solutions recently announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, IN….
vTv Therapeutics Announces $51-Million Private Placement From Healthcare-Focused Institutional Investors & the JDRF T1D Fund
vTv Therapeutics Inc. recently announced it has closed a private placement to healthcare-focused institutional investors, including a life sciences-focused institutional investor, Samsara BioCapital, LLC and…
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Silo Pharma, Inc. recently announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress…
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics & Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
Dyadic International, Inc. recently announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV, a Dutch…
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
Arch Biopartners Inc. recently announced it had a pre-investigational new drug application (PIND) meeting with the US FDA Division of Cardiovascular and Renal Products (DCRP)…
Denali Therapeutics Announces $500-Million Private Placement Equity Financing
Denali Therapeutics Inc. recently announced the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate…
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus & Replication Competent AAV Kits for Cell & Gene Therapy Production
Bio-Rad Laboratories, Inc. recently announced the launch of the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. The kits provide rapid….
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. recently announced Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating…
ABVC's New Horizon for Oncology & Hematology Aims at Cancer Market of Several Hundred Billion Dollars
ABVC BioPharma, Inc. recently provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The company is currently marketing….
Biom Pharmaceutical Published Clinical Safety & Efficacy of Microbiome-Based Probiotic Suppositories for Intimate Women's Health
Biom Pharmaceutical recently announced publication of the results of the clinical study on VagiBiom microbiome-based probiotic suppositories, the company’s flagship feminine care product. Recurring vaginal…
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program. The candidate combines….
MoonLake Immunotherapeutics Announces Positive Feedback From FDA & EMA on Regulatory Path for Phase 3 Program
MoonLake Immunotherapeutics recently announced the successful outcome of its end-of-Phase 2 interactions with the US FDA as well as positive feedback from its interactions with…
Lirum Therapeutics Presents Positive Data on Novel Clinical-Stage Targeted Therapy
Lirum Therapeutics, Inc. recently announced today it presented positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R),…
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics, Inc. recently announced completion of the single-ascending dose (SAD) cohorts for its Phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.…
